Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Feng-Ming (Spring) Kong MD PhD
Closed to Accrual
RTOG: To determine whether tumor dose can be escalated to improve the LRPF rate at 2 years when an individualized adaptive radiation treatment (RT) plan is applied by the use of a FDG-PET/CT scan acquired at 40-46 Gy initial dose of RT in patients with inoperable or unresectable stage III NSCLC
ACRIN: To determine whether the relative change in SUV/peak from the baseline to the during-treatment FDG-PET/CT, defined as (during-treatment SUVpeak - baseline SUVpeak) baseline SUVpeak X 100%, can predict the LRPF with a 2-year follow up.
See "ACRIN Information" in the left column of this page.
RT Credentialing: Please see section 5 for specific details
Data for this trial is being collected via the NRG/RTOG Data Center.
Patients with FDG-avid and histologically or cytologically proven AJCC stage IIIA or IIIB, non-operable NSCLC
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.